Barbiturate News and Research

Barbiturate is a drug used to treat insomnia, seizures, and convulsions, and to relieve anxiety and tension before surgery. It belongs to the family of drugs called central nervous system (CNS) depressants.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

The anesthetic agent ketamine has a fast-acting antidepressant effect, but that doesn't improve the response to electroconvulsive therapy (ECT) for severe depression, according to a study in the September issue of The Journal of ECT, official journal of the International Society for ECT and Neurostimulation.

Akorn, Inc., a niche generic pharmaceutical company, today announced that its wholly-owned subsidiary, Oak Pharmaceuticals, has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck A/S.

American Regent is conducting a nationwide voluntary recall to the consumer and user level of ALL unexpired lots of the following products:
Sodium Bicarbonate Injection, USP, 7.5%, 44.6 mEq/50 mL, Single Dose Vial

With reports of increased prescription drug overdoses in emergency departments, the nation's emergency physicians are issuing a strong warning to parents about the dangers of abusing prescription drugs, which are now the second most abused drugs, after marijuana. Hospital visits caused by accidental and unintentional prescription drug overdoses went up 37 percent between 1999 and 2006, according to new data released by the American Journal of Preventive Medicine.

Taro Pharmaceutical Industries Ltd. announced that the U.S. Patent and Trademark Office has issued United States Patent No. 7,683,071 covering T2007. The patent, entitled "Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid," is for one of a class of non-sedating barbiturate compounds currently in development by the Company.

Poisoning is now the second leading cause of unintentional injury death in the U.S. While several recent high-profile Hollywood celebrity cases have brought the problem to public attention, the rates of unintentional poisoning deaths have been on the rise for more than 15 years.

The nation's emergency physicians are issuing a strong warning to parents about the dangers of prescription drug abuse, which are now the second most abused drugs, after marijuana. Nearly three-quarters of a million people (741,425) needed emergency care in 2006 because of prescription drug abuse.

Taro Pharmaceutical Industries Ltd. announced that it has begun Phase I clinical trials in Canada with T2007, the second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans.

Over three decades, a world-recognized medical team at UC San Diego Medical Center has spurred the evolution of a complex surgery to destroy dangerous clusters of arteries and veins in the brain. Integrating innovative approaches in radiology, anesthesia, and surgery, the team has perfected a method to systematically starve these abnormal brain lesions, artery by artery, vein by vein.

Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug (“IND”) exemption by the United States Food and Drug Administration, (“FDA”), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.

Drug users are well informed about the harms associated with the drugs they use, and perceive alcohol and tobacco to be amongst the most dangerous substances, according to a survey by UCL (University College London) and Imperial College London researchers.

An important genetic study conducted through Mayo Clinic has identified vital new information concerning alcoholism in subjects with European ancestry, according to a recent issue of Alcohol: Clinical and Experimental Research.

A team of researchers led by investigators at the Albert Einstein College of Medicine of Yeshiva University has determined that certain commonly-prescribed medications may have the unintended consequence of increasing the frequency of migraine attacks.

There is a critical need to review current treatment strategies for the increasingly common problem of medication overuse headaches (MOH), according to a series of international papers in the November issue of Cephalalgia.

There have been clear statements from regulatory bodies that have increased the pressure on pharmaceutical companies to go electronic with their records and ensure a high level of data integrity in all areas of the pharmaceutical industry.

Other Useful Links

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.